Overview of Dr. Chandarlapaty
Dr. Sarat Chandarlapaty is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Wake Forest School of Medicine and has been in practice 15 years. He specializes in hematologic oncology.
Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2009
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2004
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2002
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2003 - 2025
Clinical Trials
- Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer Start of enrollment: 2007 Jan 09
- Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer Start of enrollment: 2010 Apr 01
Publications & Presentations
PubMed
- 244 citationsCyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patientsMaurizio Scaltriti, Pieter Johan Adam Eichhorn, Javier Cortes, Ludmila Prudkin, Claudia Aura
Proceedings of the National Academy of Sciences of the United States of America. 2011-03-01 - 413 citationsAnalysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerGaia Schiavon, Sarah Hrebien, Isaac Garcia-Murillas, Rosalind J. Cutts, Alex Pearson
Science Translational Medicine. 2015-11-11 - 577 citationsThe Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Pedram Razavi, Matthew T. Chang, Guotai Xu, Chaitanya Bandlamudi, Dara S. Ross
Cancer Cell. 2018-09-10
Journal Articles
- Article Widespread Selection for Oncogenic Mutant Allele Imbalance in CancerSarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
- Neratinib Is Effective in Breast Tumors Bearing Both Amplification and Mutation of ERBB2 (HER2)José Baselga, Kyriakos P. Papadopoulos, Sarat Chandarlapaty, David B. Solit, Science Magazine
- Immunohistochemical Analysis of Estrogen Receptor in Breast Cancer with ESR1 Mutations Detected by Hybrid Capture-Based Next-Generation SequencingMarcia Edelweiss, Edi Brogi, Dara S Ross, Fumiko Konno, Sarat Chandarlapaty, Nature
Press Mentions
MSK Research Highlights, October 15, 2024October 16th, 2024- MSK’s Research Roundup at AACR 2022: Targeted Therapy for Lung Cancer, Using Statins with a Breast Cancer Drug, and Diagnosing Blood CancerApril 11th, 2022
- SERDs Represent the Next Generation of ER-Targeting Therapy in Breast CancerJuly 31st, 2021
- Join now to see all
Grant Support
- Biologic And Therapeutic Implications Of AKT Activation In HER2+ Breast CancerNational Cancer Institute2009–2011
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHumana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
